Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability.

TL;DR: In this perception pharmacogenetics could help in the improvement of treatment response by using different medicinal approaches that would avoid potential adverse effects, reduce stabilization time and will advance the prognosis of schizophrenic patients.

TL;DR: Results indicate that although pVVNTR-S reduced CYP2C9 mRNA expression, the in vivo effects of pVN TR-S on warfarin metabolism cannot be separated from the effects of *3, and it is not necessary to consider pVnTR- S as an additional biomarker for warfar in dosing.

TL;DR: In this paper, a study was conducted to assess 3435C>T multidrug resistance 1 gene polymorphism and the efficacy of high dose methylprednisolone (HDMP) in childhood acute idiopathic thrombocytopenic purpura patients.

TL;DR: The modified HAS-BLED score, a history of bleeding, concurrent use of PPI, ABCG2 rs3114018, and ABCB1 rs1045642 were significantly associated with the risk of bleeding complications in patients on apixaban and rivaroxaban, after adjusting for other confounders.

TL;DR: A significant correlation of a polymorphism in exon 26 (C3435T) of MDR-1 with expression levels and function is observed and this polymorphism is expected to affect the absorption and tissue concentrations of numerous other substrates of M DR-1.

TL;DR: Allelic variation in MDR1 is more common than previously recognized and involves multiple SNPs whose allelic frequencies vary between populations, and some of these SNPs are associated with altered P‐glycoprotein function.

TL;DR: Some synonymous mutations in the human DRD2 have functional effects and suggest a novel genetic mechanism, calling into question some assumptions made about synonymous variation in molecular population genetics and gene-mapping studies of diseases with complex inheritance, and indicate that synonymous variation can have effects of potential pathophysiological and pharmacogenetic importance.

TL;DR: SNPs in MDR1 in relation to population frequencies, drug levels, and phenotypes are outlined and issues relating to M DR1 haplotypes, environmental factors, and study design, as potential confounding factors of the observed MDR 1 polymorphism effect in vivo, are discussed.